J Ilonen1, M Kiviniemi1, J Lempainen1, O Simell2,3, J Toppari2,3,4, R Veijola5,6, M Knip7,8,9. 1. Immunogenetics Laboratory, University of Turku, Turku, Finland. 2. Department of Pediatrics, University of Turku, Turku, Finland. 3. Department of Pediatrics, Turku University Hospital, Turku, Finland. 4. Department of Physiology, University of Turku, Turku, Finland. 5. Department of Pediatrics, University of Oulu, PEDEGO Research Unit, MRC Oulu, Oulu, Finland. 6. Department of Pediatrics, Oulu University Hospital, Oulu, Finland. 7. Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 8. Folkhälsan Research Center, Helsinki, Finland. 9. Department of Pediatrics, Tampere University Hospital, Tampere, Finland.
Abstract
OBJECTIVE: The HLA-DR/DQ region remains the major determinant of susceptibility to type 1 diabetes (T1D) despite the more than 50 risk affecting loci outside human leukocyte antigen (HLA) region that have been identified. We aimed at developing a simple risk estimation based on HLA class II genotyping, which was also tested by analyzing HLA class II effect on the autoantibody seroconversion and further progression to diabetes. SUBJECTS AND METHODS: A total of 2991 trio families with a diabetic child from the Finnish Pediatric Diabetes Register were genotyped and the risk contributed by each DR-DQ haplotype calculated through transmission analysis. The genotype risk was estimated based on the summary effect of haplotypes. Genotype grouping was further tested in a subcohort of the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study RESULTS: The summary effect of haplotypes was generally seen in genotypes, while the expected synergistic effect of DR3-DQ2 and DR4-DQ8 (DRB1*04:03 excluded) combination was also clear in the T1D risk association analysis. This highest risk DR/DQ genotype was found in 21.6% of patients and 2.0% of controls, odds ratio (OR) = 13.2 (10.1-17.2), whereas the lowest risk genotype contained only 0.8% of patients and 28.0% of controls, OR = 0.02 (0.01-0.03). In the subcohort from the DIPP study the risk grades correlated clearly with seroconversion for islet autoantibodies and T1D development. In contrast, DR/DQ risk groups did not associate with the progression rate from advanced autoimmunity to clinical diabetes. CONCLUSIONS: Class II HLA genotype groups improve the estimation of T1D risk. Class II effect is limited to the early phase of the disease process characterized by seroconversion for islet autoantibodies.
OBJECTIVE: The HLA-DR/DQ region remains the major determinant of susceptibility to type 1 diabetes (T1D) despite the more than 50 risk affecting loci outside human leukocyte antigen (HLA) region that have been identified. We aimed at developing a simple risk estimation based on HLA class II genotyping, which was also tested by analyzing HLA class II effect on the autoantibody seroconversion and further progression to diabetes. SUBJECTS AND METHODS: A total of 2991 trio families with a diabeticchild from the Finnish Pediatric Diabetes Register were genotyped and the risk contributed by each DR-DQ haplotype calculated through transmission analysis. The genotype risk was estimated based on the summary effect of haplotypes. Genotype grouping was further tested in a subcohort of the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study RESULTS: The summary effect of haplotypes was generally seen in genotypes, while the expected synergistic effect of DR3-DQ2 and DR4-DQ8 (DRB1*04:03 excluded) combination was also clear in the T1D risk association analysis. This highest risk DR/DQ genotype was found in 21.6% of patients and 2.0% of controls, odds ratio (OR) = 13.2 (10.1-17.2), whereas the lowest risk genotype contained only 0.8% of patients and 28.0% of controls, OR = 0.02 (0.01-0.03). In the subcohort from the DIPP study the risk grades correlated clearly with seroconversion for islet autoantibodies and T1D development. In contrast, DR/DQ risk groups did not associate with the progression rate from advanced autoimmunity to clinical diabetes. CONCLUSIONS: Class II HLA genotype groups improve the estimation of T1D risk. Class II effect is limited to the early phase of the disease process characterized by seroconversion for islet autoantibodies.
Authors: Amir-Babak Sioofy-Khojine; Jussi Lehtonen; Noora Nurminen; Olli H Laitinen; Sami Oikarinen; Heini Huhtala; Outi Pakkanen; Tanja Ruokoranta; Minna M Hankaniemi; Jorma Toppari; Mari Vähä-Mäkilä; Jorma Ilonen; Riitta Veijola; Mikael Knip; Heikki Hyöty Journal: Diabetologia Date: 2018-02-05 Impact factor: 10.122
Authors: Hanna Honkanen; Sami Oikarinen; Noora Nurminen; Olli H Laitinen; Heini Huhtala; Jussi Lehtonen; Tanja Ruokoranta; Minna M Hankaniemi; Valérie Lecouturier; Jeffrey W Almond; Sisko Tauriainen; Olli Simell; Jorma Ilonen; Riitta Veijola; Hanna Viskari; Mikael Knip; Heikki Hyöty Journal: Diabetologia Date: 2017-01-09 Impact factor: 10.122
Authors: Mikael Knip; Hans K Åkerblom; Eva Al Taji; Dorothy Becker; Jan Bruining; Luis Castano; Thomas Danne; Carine de Beaufort; Hans-Michael Dosch; John Dupre; William D Fraser; Neville Howard; Jorma Ilonen; Daniel Konrad; Olga Kordonouri; Jeffrey P Krischer; Margaret L Lawson; Johnny Ludvigsson; Laszlo Madacsy; Jeffrey L Mahon; Anne Ormisson; Jerry P Palmer; Paolo Pozzilli; Erkki Savilahti; Manuel Serrano-Rios; Marco Songini; Shayne Taback; Outi Vaarala; Neil H White; Suvi M Virtanen; Renata Wasikowa Journal: JAMA Date: 2018-01-02 Impact factor: 56.272
Authors: Brigitte I Frohnert; Michael Laimighofer; Jan Krumsiek; Fabian J Theis; Christiane Winkler; Jill M Norris; Anette-Gabriele Ziegler; Marian J Rewers; Andrea K Steck Journal: Pediatr Diabetes Date: 2017-07-11 Impact factor: 4.866
Authors: Hanna Viskari; Sami Oikarinen; Sanna Hoppu; Tytti Vuorinen; Heini Huhtala; Jorma Toppari; Riitta Veijola; Jorma Ilonen; Mikael Knip; Heikki Hyöty Journal: Diabetologia Date: 2017-09-02 Impact factor: 10.122
Authors: Moran Yassour; Eeva Jason; Larson J Hogstrom; Timothy D Arthur; Surya Tripathi; Heli Siljander; Jenni Selvenius; Sami Oikarinen; Heikki Hyöty; Suvi M Virtanen; Jorma Ilonen; Pamela Ferretti; Edoardo Pasolli; Adrian Tett; Francesco Asnicar; Nicola Segata; Hera Vlamakis; Eric S Lander; Curtis Huttenhower; Mikael Knip; Ramnik J Xavier Journal: Cell Host Microbe Date: 2018-07-11 Impact factor: 21.023
Authors: Rossana Santiago de Sousa Azulay; Luís Cristóvão Porto; Dayse Aparecida Silva; Maria da Glória Tavares; Roberta Maria Duailibe Ferreira Reis; Gilvan Cortês Nascimento; Sabrina da Silva Pereira Damianse; Viviane Chaves de Carvalho Rocha; Marcelo Magalhães; Vandilson Rodrigues; Paulo Ricardo Vilas Boas Carvalho; Manuel Dos Santos Faria; Marília Brito Gomes Journal: Sci Rep Date: 2021-07-08 Impact factor: 4.379